• English
    • العربية
  • العربية
  • Login
  • QU
  • QU Library
  •  Home
  • Communities & Collections
  • Help
    • Item Submission
    • Publisher policies
    • User guides
    • FAQs
  • About QSpace
    • Vision & Mission
View Item 
  •   Qatar University Digital Hub
  • Qatar University Institutional Repository
  • Academic
  • Research Units
  • Biomedical Research Center
  • Biomedical Research Center Research
  • View Item
  • Qatar University Digital Hub
  • Qatar University Institutional Repository
  • Academic
  • Research Units
  • Biomedical Research Center
  • Biomedical Research Center Research
  • View Item
  •      
  •  
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study

    Thumbnail
    View/Open
    Publisher version (You have accessOpen AccessIcon)
    Publisher version (Check access options)
    Check access options
    Date
    2023-03-10
    Author
    Hiam, Chemaitelly
    Ayoub, Houssein H
    Tang, Patrick
    Coyle, Peter
    Yassine, Hadi M
    Al Thani, Asmaa A
    Al-Khatib, Hebah A
    Hasan, Mohammad R
    Al-Kanaani, Zaina
    Al-Kuwari, Einas
    Jeremijenko, Andrew
    Kaleeckal, Anvar Hassan
    Latif, Ali Nizar
    Shaik, Riyazuddin Mohammad
    Abdul-Rahim, Hanan F
    Nasrallah, Gheyath K
    Al-Kuwari, Mohamed Ghaith
    Butt, Adeel A
    Al-Romaihi, Hamad Eid
    Al-Thani, Mohamed H
    Al-Khal, Abdullatif
    Bertollini, Roberto
    Faust, Jeremy Samuel
    Abu-Raddad, Laith J
    ...show more authors ...show less authors
    Metadata
    Show full item record
    Abstract
    BackgroundLong-term effectiveness of COVID-19 mRNA boosters in populations with different previous infection histories and clinical vulnerability profiles is inadequately understood. We aimed to investigate the effectiveness of a booster (third dose) vaccination against SARS-CoV-2 infection and against severe, critical, or fatal COVID-19, relative to that of primary-series (two-dose) vaccination over a follow-up duration of 1 year. MethodsThis observational, matched, retrospective, cohort study was done on the population of Qatar in people with different immune histories and different clinical vulnerability to infection. The source of data are Qatar's national databases for COVID-19 laboratory testing, vaccination, hospitalisation, and death. Associations were estimated using inverse-probability-weighted Cox proportional-hazards regression models. The primary outcome of the study is the effectiveness of COVID-19 mRNA boosters against infection and against severe COVID-19. FindingsData were obtained for 2 228 686 people who had received at least two vaccine doses starting from Jan 5, 2021, of whom 658 947 (29·6%) went on to receive a third dose before data cutoff on Oct 12, 2022. There were 20 528 incident infections in the three-dose cohort and 30 771 infections in the two-dose cohort. Booster effectiveness relative to primary series was 26·2% (95% CI 23·6–28·6) against infection and 75·1% (40·2–89·6) against severe, critical, or fatal COVID-19, during 1-year follow-up after the booster. Among people clinically vulnerable to severe COVID-19, effectiveness was 34·2% (27·0–40·6) against infection and 76·6% (34·5–91·7) against severe, critical, or fatal COVID-19. Effectiveness against infection was highest at 61·4% (60·2–62·6) in the first month after the booster but waned thereafter and was modest at only 15·5% (8·3–22·2) by the sixth month. In the seventh month and thereafter, coincident with BA.4/BA.5 and BA.2·75* subvariant incidence, effectiveness was progressively negative albeit with wide CIs. Similar patterns of protection were observed irrespective of previous infection status, clinical vulnerability, or type of vaccine (BNT162b2 vs mRNA-1273). InterpretationProtection against omicron infection waned after the booster, and eventually suggested a possibility for negative immune imprinting. However, boosters substantially reduced infection and severe COVID-19, particularly among individuals who were clinically vulnerable, affirming the public health value of booster vaccination. FundingThe Biomedical Research Program and the Biostatistics, Epidemiology, and the Biomathematics Research Core (both at Weill Cornell Medicine-Qatar), Ministry of Public Health, Hamad Medical Corporation, Sidra Medicine, Qatar Genome Programme, and Qatar University Biomedical Research Center.
    URI
    https://www.sciencedirect.com/science/article/pii/S1473309923000580
    DOI/handle
    http://dx.doi.org/10.1016/S1473-3099(23)00058-0
    http://hdl.handle.net/10576/41367
    Collections
    • Biomedical Research Center Research [‎786‎ items ]
    • Biomedical Sciences [‎802‎ items ]
    • COVID-19 Research [‎848‎ items ]
    • Mathematics, Statistics & Physics [‎786‎ items ]
    • Public Health [‎484‎ items ]

    entitlement


    Qatar University Digital Hub is a digital collection operated and maintained by the Qatar University Library and supported by the ITS department

    Contact Us | Send Feedback
    Contact Us | Send Feedback | QU

     

     

    Home

    Submit your QU affiliated work

    Browse

    All of Digital Hub
      Communities & Collections Publication Date Author Title Subject Type Language Publisher
    This Collection
      Publication Date Author Title Subject Type Language Publisher

    My Account

    Login

    Statistics

    View Usage Statistics

    About QSpace

    Vision & Mission

    Help

    Item Submission Publisher policiesUser guides FAQs

    Qatar University Digital Hub is a digital collection operated and maintained by the Qatar University Library and supported by the ITS department

    Contact Us | Send Feedback
    Contact Us | Send Feedback | QU

     

     

    Video